Alkermes upped its bid on Avadel to $2.37 billion on Wednesday, coming in with the "superior proposal" vs. Lundbeck's unexpected pitch.

Alkermes ALKS announced that it has now increased the offer to acquire Ireland-based Avadel Pharmaceuticals AVDL in a deal ...

Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4 ...

Alkermes is drafting a former Major League Baseball player who has struggled with his own alcohol addiction as spokesperson for its alcohol dependency awareness campaign. World Series winner and ...

Alkermes reported third quarter 2025 earnings from continuing operations of 49 cents per share, surpassing expectations, with sales of its proprietary products portfolio growing 16% year over year due ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Alkermes plans to spin out its oncology research division into a standalone entity, creating a potential value-unlocking transaction. The spin-off will allow Alkermes to focus on its neuroscience ...

(Reuters) - Drugmaker Alkermes said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for schizophrenia and bipolar disorder, citing concerns related to a tablet ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Brain drug developer Alkermes could spend billions of ...

Alkermes has a portfolio of commercialized neuroscience products and a pipeline that spans both neuroscience and cancer. The drugmaker is now exploring the possibility of splitting off its cancer ...